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AUTOANTIBODIES have been demon-
strated in patients with various malignant
diseases, including breast cancer, but the
reports have been somewhat conflicting.
Whitehouse & Holborow (1971) found that
smooth-muscle antibody and antinuclear
factor occurred more frequently in cancer
patients. Similarly, Wasserman et at.
(1975) found a raised incidence ofsmooth-
muscle and antinuclear antibodies in
breast-cancer patients, and 20% of all the
cancer patients they studiedhadmorethan
one antibody. These patients had a worse
prognosis. Further studies have confirmed
the raised incidence of antinuclear factor
in malignant disease (Burnham, 1972;
Zeromski et al., 1972). However, Tannen-
bergetal. (1973)reportedthattheincidence
of autoantibodies in cancer patients was
less than in patients with non-malignant
diseases and Mittra et al. (1976) found a
similar incidence of thyroid antibodies in
breast-cancer patients and healthy con-
trols. They also found that the incidence
of 6 other autoantibodies was not raised
in breast-cancer patients.
In an attempt to clarify the situation,
the incidence of autoantibodies in breast
cancer has been examined further in
patients with early breast cancer.
Patients
The patients form part of a unicentric
randomized prospective clinical trial com-
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paring simple mastectomy alone with
simple mastectomy plus radical radio-
therapy as a treatment for early breast
cancer (Turnbull et al., 1978). Ninety-six
patients were studied, ofwhom 46 received
radiotherapy (DXT); the remaining 50
were closely observed (OB).
An axillary-lymphnode biopsy was
routinely performed at operation. In addi-
tion, the patients were skin-tested pre-
operatively with 3 recall antigens (10 units
of purified protein derivative, 0-02 ml of
0.5% Candida albicans (Bencard) and 10
units of Varidase (streptokinase/strepto-
dornase). Fifty-one age- and sex-matched
controls were taken from a hospital
visitors' control panel.
Autoantibodies
Sera were obtained from the patients
preoperatively, and 6 months later. All the
tests were carried out on the patients and
controls at the same time, the sera having
been stored at -20TC. The samesubstrates
and conjugates were used throughout.
The sera were diluted 1:10 and tested
by indirect immunofluorescence against
unfixed sections of human thyroid, rat
stomach, mouse stomach, rat kidney, rat
liver and rat salivary gland, as previously
described (Triger et at., 1976). The sera
were tested using either a monovalent or
a polyvalent antihuman-Ig antiserum,
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conjugatedwithfluoresceinisothiocyanate,
as appropriate.
Thyroglobulin antibodies and rheuma-
toid factor were detected by the tanned
red cell method of Boyden (1951) and by
haemagglutination (Ball, 1952).
TABLE II.-Incidence ofautoantibodies
Patients
Controls
P<0 05.
No
autoantibodies
36 (37%)
27 (530)
Autoantibodies
present
60 (63%)
24 (47%)
Statistics
The Chi-square test with Yates' correc-
tion, the exact test or Student's t test were
used as appropriate.
RESULTS
The incidence ofautoantibodiesdetected
in the patients and controls is shown in
Table I. There is no significant difference
TABLE I.-Incidence of individual
autoantibodies
Antibody
Thyroid microsomal
Thyroglobulin
Gastric parietal cell
Antinuclear
Smooth muscle
Mitochondrial
Skeletal muscle
Reticulin
Rheumatoid factor
Patients
(96)
12 (13%)
0
9 (9%)
14 (15%)
5 (5%)
0
4 (4%)
1 (1/%)
6 (6%)
Controls
(51)
8 (16%)
1 (2%)
3 (6%)
3 (6%)
4 (8%)
2 (4%)
0
2 (4%)
2 (4%)
in the individual antibodies between the
two groups. Eighty-eight patients showed
no change in their autoimmunity profiles
from the preoperative specimen to the 6-
months postoperative specimen, and radi-
cal radiotherapy did not alter theincidence
of autoantibodies. Minor insignificant
changes occurred in the other 8 patients.
Autoantibodies occurred significantly
more frequently in the breast-cancer
patients than in controls (Table II) but
the incidence of more than one antibody
in any individual was not greater.
There were 60 patients whose sera con-
tained one or more autoantibodies, and 36
in whom no autoantibodies were found.
The mean ages of the 2 groups were the
same: 55-35 years (s.d. 8.40) and 55-72
years (s.d. 9.64) respectively. This com-
pares with the mean age of 24 controls
with autoantibodies present of 54-83 (s.d.
10.5) and 27 negative controls of 52-59
(s.d. 9.62). None of these differences is
significant.
Table III shows the frequency of anti-
nuclear antibody (ANA) in relation to
lymphnode histology and skin tests (ST).
The axillary lymph nodes were examined
in 84 patients: 42 had histological evidence
of tumour involvement (LN+) and 42 had
no evidence of spread to the axilla (LN-).
No ANA was found in the LN- group, but
a total of 10 (24%) LN+ patients had ANA
in their serum (P<0.001). Seven of these
patients were positive for IgG ANA and
9 for IgM ANA. In the remaining 4 ANA+
patients lymphnode histology was not
available. Sixteen patients did not react to
any ofthe 3 recall antigens. The incidence
of ANA in these patients was 31% which
was significantly greater than the 11% I
incidence found in the skin-test-reactive
patients (P<0-05).
TABLE III.-Incidence of antinuclear antibody in early breast-cancer patients in relation
to lymphnode histology and skin tests
Antinuclear antibody LN+* LN- ST+t
positive 10t (24%) 0 9 (11%)
negative 32 (760%) 42 (l100%) 71 (89o%)
*=Histological evidence of tumour involvement in axillary lymph nodes.
t Positive reaction to one or more of 3 recall antigens.
t =P<O*001.
§ =P<0 05.
ST-
5§ (31%)
11 (69/o)
Controls
3 (6%)
48 (94%)
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Eleven patients had either died or de-
veloped distant metastases within the
first 12 months, but the incidence of auto-
antibodies in this group was comparable
with that in the 85 patients who had no
evidence of widespread dissemination at
this time.
DISCUSSION
We have found that the incidence of
individual autoantibodies in patients with
early breast cancer is not significantly
greater than in a control population. This
finding is consistent with that of Mittra et
al. (1976). However, overall there is an
increased incidence of autoantibodies in
the cancer patients, with 63% giving posi-
tive results in one or more of the major
antigen-antibody systems tested, com-
pared with 47% in the control group. The
incidence of more than one antibody in
individual patients was not increased.
A striking difference was noted in the
incidence of antinuclear antibody in pa-
tients with lymphnode metastases: 24% of
patients who had developed spread to the
axilla gave positive results, whereas no
patient with a negative lymphnode biopsy
had antinuclear antibody. This stage-
related difference might well account for
the previous variations in incidence which
have been reported in the literature.
The incidence ofautoantibodies was not
altered by surgery or radical radiotherapy.
The preoperative autoimmune profiles
were virtually identical with the 6-months
postoperative results in both irradiated
and observed patients.
Age did not appear to be a contributory
factor. The mean age of patients showing
one or more antibodies in their sera was
the same as the mean age ofthose patients
with no antibodies, and similar to the
mean age ofthe controls. This finding is in
agreement with that of Gray et al. (1975),
who reported that there was no age-related
increase in incidence of autoantibodies in
cancer patients.
Antinuclear antibody was present more
frequently (31%) in anergic patients than
in skin-test-reactive patients (11%). This
would be expected if they both correlate
with a state of immunodeficiency.
At 12 months there was no correlation
between individual autoantibodies and
clinical outcome. However, a stage-related
increased incidence of ANA was noted,
and since Stage II breast-cancer patients
have a worse prognosis, a correlation may
become apparent with longer follow-up.
In conclusion, this study has shown that
the incidence ofautoantibodies isincreased
in early breast cancer. Of particular in-
terest is the fact that the presence of anti-
nuclear antibody, previously reported in
cancer patients, appears to be a stage-
related phenomenon.
The study was supported by Tenovus of Cardiff
and the Wellcome Trust. The manuscript was typed
by Mrs C. Bright.
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